Side Effects of mRNA-Based COVID-19 Vaccine: Nationwide Phase IV Study among Healthcare Workers in Slovakia

Investor logo

Warning

This publication doesn't include Institute of Computer Science. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

RIAD Abanoub HOCKOVÁ Barbora KANTOROVÁ Lucia SLÁVIK Rastislav SPURNÁ Lucia STEBEL Adam HAVRIĽAK Michal KLUGAR Miloslav

Year of publication 2021
Type Article in Periodical
Magazine / Source Pharmaceuticals
MU Faculty or unit

Faculty of Medicine

Citation
Web https://www.mdpi.com/1424-8247/14/9/873
Doi http://dx.doi.org/10.3390/ph14090873
Keywords BNT162b2 vaccine; cross-sectional studies; COVID-19; drug-related side effects and adverse reactions; health personnel; mass vaccination; prevalence
Description mRNA-based COVID-19 vaccines such as BNT162b2 have recently been a target of anti-vaccination campaigns due to their novelty in the healthcare industry; nevertheless, these vaccines have exhibited excellent results in terms of efficacy and safety. As a consequence, they acquired the first approvals from drug regulators and were deployed at a large scale among priority groups, including healthcare workers. This phase IV study was designed as a nationwide cross-sectional survey to evaluate the post-vaccination side effects among healthcare workers in Slovakia. The study used a validated self-administered questionnaire that inquired about participants’ demographic information, medical anamneses, COVID-19-related anamnesis, and local, systemic, oral, and skin-related side effects following receiving the BNT162b2 vaccine. A total of 522 participants were included in this study, of whom 77% were females, 55.7% were aged between 31 and 54 years, and 41.6% were from Banska Bystrica. Most of the participants (91.6%) reported at least one side effect. Injection site pain (85.2%) was the most common local side effect, while fatigue (54.2%), headache (34.3%), muscle pain (28.4%), and chills (26.4%) were the most common systemic side effects. The reported side effects were of a mild nature (99.6%) that did not require medical attention and a short duration, as most of them (90.4%) were resolved within three days. Females and young adults were more likely to report post-vaccination side effects; such a finding is also consistent with what was previously reported by other phase IV studies worldwide. The role of chronic illnesses and medical treatments in post-vaccination side effect incidence and intensity requires further robust investigation among large population groups.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info